These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 23294549)

  • 21. Is contraceptive self-injection cost-effective compared to contraceptive injections from facility-based health workers? Evidence from Uganda.
    Di Giorgio L; Mvundura M; Tumusiime J; Morozoff C; Cover J; Drake JK
    Contraception; 2018 Nov; 98(5):396-404. PubMed ID: 30098940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Young Women's Experiences With Subcutaneous Depot Medroxyprogesterone Acetate: A Secondary Analysis of a One-Year Randomized Trial in Malawi.
    Burke HM; Chen M; Packer C; Fuchs R; Ngwira B
    J Adolesc Health; 2020 Nov; 67(5):700-707. PubMed ID: 32389457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Costs of administering injectable contraceptives through health workers and self-injection: evidence from Burkina Faso, Uganda, and Senegal.
    Di Giorgio L; Mvundura M; Tumusiime J; Namagembe A; Ba A; Belemsaga-Yugbare D; Morozoff C; Brouwer E; Ndour M; Drake JK
    Contraception; 2018 Nov; 98(5):389-395. PubMed ID: 29859148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient's experience and satisfaction with self-administered subcutaneous depot medroxyprogesterone acetate use during the first year of COVID-19.
    Smith TJ; Urdanigo TK; Shroff N; Rubin SE
    Contraception; 2023 Jul; 123():110008. PubMed ID: 36931548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expanding Access to Injectable Contraception: Results From Pilot Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in 4 African Countries.
    Stout A; Wood S; Barigye G; Kaboré A; Siddo D; Ndione I
    Glob Health Sci Pract; 2018 Mar; 6(1):55-72. PubMed ID: 29602866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in weight with depot medroxyprogesterone acetate subcutaneous injection 104 mg/0.65 mL.
    Westhoff C; Jain JK; Milsom I; Ray A
    Contraception; 2007 Apr; 75(4):261-7. PubMed ID: 17362703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluating the feasibility and acceptability of self-injection of subcutaneous depot medroxyprogesterone acetate (DMPA) in Senegal: a prospective cohort study.
    Cover J; Ba M; Lim J; Drake JK; Daff BM
    Contraception; 2017 Sep; 96(3):203-210. PubMed ID: 28673645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Would you be interested in DMPA-SC? An implementation project in two urban primary care clinics.
    Miles C; Ennamuri D; Yeh J; Shih G
    Contraception; 2022 Aug; 112():116-119. PubMed ID: 35123982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Observational study of the acceptability of Sayana® Press among intramuscular DMPA users in Uganda and Senegal.
    Burke HM; Mueller MP; Perry B; Packer C; Bufumbo L; Mbengue D; Mall I; Daff BM; Mbonye AK
    Contraception; 2014 May; 89(5):361-7. PubMed ID: 24631328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Introduction of Community-Based Provision of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in Benin: Programmatic Results.
    Okegbe T; Affo J; Djihoun F; Zannou A; Hounyo O; Ahounou G; Bangbola KA; Harris N
    Glob Health Sci Pract; 2019 Jun; 7(2):228-239. PubMed ID: 31171559
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adolescent and covert family planning users' experiences self-injecting contraception in Uganda and Malawi: implications for waste disposal of subcutaneous depot medroxyprogesterone acetate.
    Burke HM; Packer C; Wando L; Wandiembe SP; Muwereza N; Pradhan S; Zingani A; Ngwira B
    Reprod Health; 2020 Aug; 17(1):117. PubMed ID: 32746860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Society of Family Planning committee consensus on self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA-SC).
    Kohn JE; Berlan ED; Tang JH; Beasley A
    Contraception; 2022 Aug; 112():11-13. PubMed ID: 35378085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) Injectable Contraception at Facility and Community Levels: Pilot Results From 4 Districts of Uganda.
    Odwe G; Gray K; Kyarimpa A; Obare F; Nagendi G
    Glob Health Sci Pract; 2018 Dec; 6(4):711-722. PubMed ID: 30429201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update to U.S. Selected Practice Recommendations for Contraceptive Use: Self-Administration of Subcutaneous Depot Medroxyprogesterone Acetate.
    Curtis KM; Nguyen A; Reeves JA; Clark EA; Folger SG; Whiteman MK
    MMWR Morb Mortal Wkly Rep; 2021 May; 70(20):739-743. PubMed ID: 34014910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial.
    Nanda K; Callahan R; Taylor D; Wang M; Agot K; Jenkins D; Van Damme L; Dorflinger L;
    Contraception; 2016 Jul; 94(1):40-7. PubMed ID: 26972780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient satisfaction of depot medroxyprogesterone acetate (dmpa-sc) injection as contraceptive.
    Chaudhri R; Rizvi F; Afzal M
    J Pak Med Assoc; 2010 Jul; 60(7):536-40. PubMed ID: 20578601
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An observational study to test the acceptability and feasibility of using medical and nursing students to instruct clients in DMPA-SC self-injection at the community level in Kinshasa.
    Bertrand JT; Bidashimwa D; Makani PB; Hernandez JH; Akilimali P; Binanga A
    Contraception; 2018 Nov; 98(5):411-417. PubMed ID: 30120925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implementation strategies to scale up self-administered depot medroxyprogesterone acetate subcutaneous injectable contraception: a scoping review.
    Aderoba AK; Steyn PS; Kiarie JN
    Syst Rev; 2023 Jul; 12(1):114. PubMed ID: 37403147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg.
    Arias RD; Jain JK; Brucker C; Ross D; Ray A
    Contraception; 2006 Sep; 74(3):234-8. PubMed ID: 16904417
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Introducing the subcutaneous depot medroxyprogesterone acetate injectable contraceptive via social marketing: lessons learned from Nigeria's private sector.
    Liu J; Schatzkin E; Omoluabi E; Fajemisin M; Onuoha C; Erinfolami T; Ayodeji K; Ogunmola S; Shen J; Diamond-Smith N; Sieverding M
    Contraception; 2018 Nov; 98(5):438-448. PubMed ID: 30071196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.